These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24231646)

  • 21. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil.
    Kimball JA; Pescovitz MD; Book BK; Norman DJ
    Transplantation; 1995 Dec; 60(12):1379-83. PubMed ID: 8545860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful rescue therapy with mycophenolate mofetil in kidney transplantation improves the long-term graft survival.
    Kahu J; Lõhmus A; Ilmoja M; Kirsimägi U; Timberg G; Peetsalu A
    Medicina (Kaunas); 2007; 43(12):953-8. PubMed ID: 18182839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of long-term actual renal allograft survival in mycophenolate mofetil and azathioprine-based triple drug immunosuppression protocols.
    Attallah N; Goggins M; Nori U; Abouljoud M; Zasuwa G; Venkat KK; Parasuraman R
    Transplant Proc; 2005 Jun; 37(5):2060-2. PubMed ID: 15964338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation.
    Fangmann J; Arns W; Marti HP; Hauss J; Ketteler M; Beckurts T; Boesmueller C; Pohanka E; Martin PY; Gerhardt M; Farese S; Neumayer HH; Floege J; Gurr C; Budde K;
    Nephrol Dial Transplant; 2010 Jan; 25(1):283-92. PubMed ID: 19773417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil.
    Kaczmarek I; Ertl B; Schmauss D; Sadoni S; Knez A; Daebritz S; Meiser B; Reichart B
    J Heart Lung Transplant; 2006 May; 25(5):550-6. PubMed ID: 16678034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study.
    Neu AM; Ho PL; Fine RN; Furth SL; Fivush BA
    Pediatr Transplant; 2003 Jun; 7(3):217-22. PubMed ID: 12756047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of immunosuppressive treatment on homocystein levels in patients after kidney transplantation during a 2 year observation period].
    Aksamit D; Janda K; Kuźniewski M; Krzanowski M; Ignacak E; Betkowska-Prokop A; Chowaniec E; Sułowicz W
    Przegl Lek; 2012; 69(11):1175-9. PubMed ID: 23646442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
    Bataille S; Moal V; Gaudart J; Indreies M; Purgus R; Dussol B; Zandotti C; Berland Y; Vacher-Coponat H
    Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.
    Opelz G; Döhler B;
    Transplantation; 2009 Mar; 87(6):795-802. PubMed ID: 19300179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mycophenolate mofetil severely depresses antibody response to CMV infection in early posttransplant period.
    Zmonarski SC; Boratynska M; Madziarska K; Klinger M; Kusztel M; Patrzalek D; Szyber P
    Transplant Proc; 2003 Sep; 35(6):2205-6. PubMed ID: 14529889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maintenance immunosuppression with mycophenolate mofetil: long-term efficacy and safety after heart transplantation.
    Dandel M; Jasaityte R; Lehmkuhl H; Knosalla C; Hetzer R
    Transplant Proc; 2009; 41(6):2585-8. PubMed ID: 19715979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up.
    Lee YJ; Kim B; Lee JE; Kim YG; Kim DJ; Kim SJ; Joh JW; Oh HY; Huh W
    Transpl Int; 2010 Feb; 23(2):147-54. PubMed ID: 19744223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
    El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA
    Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term graft outcome in patients with chronic allograft dysfunction after immunosuppression modifications.
    El-Agroudy AE; El-Dahshan K; Mahmoud K; El-Baz M; Shokeir AA; Ghoneim MA
    Ann Transplant; 2008; 13(4):46-54. PubMed ID: 19034223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil.
    Weimer R; Süsal C; Yildiz S; Streller S; Pelzl S; Staak A; Renner F; Dietrich H; Daniel V; Feuring E; Kamali-Ernst S; Ernst W; Padberg W; Opelz G
    Transplant Proc; 2005 May; 37(4):1776-8. PubMed ID: 15919463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of initial immunosuppression on long-term kidney transplant outcome in immunological low-risk patients.
    Michielsen LA; van Zuilen AD; Verhaar MC; Wisse BW; Kamburova EG; Joosten I; Allebes WA; van der Meer A; Baas MC; Spierings E; Hack CE; van Reekum FE; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JF; Hepkema BG; Lambeck AJ; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG; Hilbrands LB
    Nephrol Dial Transplant; 2019 Aug; 34(8):1417-1422. PubMed ID: 30561730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo.
    Rentenaar RJ; van Diepen FN; Meijer RT; Surachno S; Wilmink JM; Schellekens PT; Pals ST; van Lier RA; ten Berge IJ
    Kidney Int; 2002 Jul; 62(1):319-28. PubMed ID: 12081594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alemtuzumab induction in deceased donor kidney transplantation.
    Huang E; Cho YW; Hayashi R; Bunnapradist S
    Transplantation; 2007 Oct; 84(7):821-8. PubMed ID: 17984833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.